News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. consumer CPI fell 0.4% in June, the largest monthly decline since April 2020, while core CPI was unchanged, softening inflation readings.
  • Citi posted a 45% jump in Q2 net income and decade-high revenue, while Bank of America beat Q2 estimates but saw shares slip pre-market.
  • IBM's weak preliminary Q2 preview sparked a selloff in enterprise software, sending Workday sharply lower amid mounting insider sales concerns.
  • KeyBanc hiked Texas Instruments' price target to $390, lifting TI stock ahead of Q2 and boosting semiconductor premarket momentum.
  • Kratos said about $400 million of new Department of Defense funding tied to hypersonic programs began flowing, lifting expected organic growth and cash receipts.
  • Liberty Energy partnered with SLB to offer modular data-center infrastructure and power systems, driving a roughly 3% pre-market share rise.
  • Australia will create an Office of AI within the Prime Minister's department to centralize AI policy, approvals and standards across government.

Latest Articles

Orban Reaffirmed as Fidesz Leader for Another Year Despite April Election Defeat

Orban Reaffirmed as Fidesz Leader for Another Year Despite April Election Defeat

Viktor Orban was re-elected as leader of Hungary's Fidesz party for a further year by an almost unanimous delegate vote, despite the party's loss of power in the April 12 election to the centre-right Tisza party. Orban, 62, who coined an 'illiberal' model of governance and has influenced right-wing movements abroad, faced internal pressure to step …

Why ArcelorMittal Is Poised to Benefit from Steel Import Controls

Why ArcelorMittal Is Poised to Benefit from Steel Import Controls

ArcelorMittal (MT) trades near $70.81 after a year of operational improvements, capital returns and a clear decarbonization plan. New and prospective import controls on steel in North America and elsewhere are a direct demand/price tailwind for integrated steelmakers. Combine policy support with a $53.9B market cap, €1.3bn investment in an electric…

Applied Optoelectronics: Betting on the Laser Bottleneck Winner

Applied Optoelectronics: Betting on the Laser Bottleneck Winner

Applied Optoelectronics (AAOI) has become a go-to supplier for optical transceivers and laser diodes as hyperscalers and AI data-center builders accelerate connectivity spending. The stock has already rallied dramatically, but balance-sheet strength, tight short interest and clear demand catalysts make a tactical long attractive from current levels…

AppLovin's Axon Moment: Betting on AI to Supercharge Ad Conversion

AppLovin's Axon Moment: Betting on AI to Supercharge Ad Conversion

AppLovin (APP) is trading like a growth software name with monster profitability. Strong Q1 prints and the roll-out of Axon AI have pushed revenue and margins higher; the market is pricing a premium (P/E ~42, P/S ~27). This trade idea outlines a disciplined long with entry at $497.00, stop at $430.00 and a $650.00 target over a 180 trading-day hori…

Electromed: High-Margin Medical Device Growth with Clear Upside

Electromed: High-Margin Medical Device Growth with Clear Upside

Electromed (ELMD) is a compact medical-specialties company punching above its weight: roughly $72M of implied revenue, double-digit free cash flow margins, zero debt and solid returns on capital. Technicals are constructive and the stock trades below a recent $40 52-week high. We outline a long trade with a $37.00 entry, $33.00 stop and $45.00 targ…

RH: Luxury Furniture at a Discount — Buy the Dip, Respect the Risks

RH: Luxury Furniture at a Discount — Buy the Dip, Respect the Risks

RH (Restoration Hardware) is a high-end furniture and home-lifestyle name trading well below prior highs despite solid free cash flow, expanding international presence, and continued pricing power. At roughly $153, shares offer asymmetric upside to $220 over a multi-month horizon while offering an attractive free cash flow yield; downside is real, …

Memory Price Surge Sparks Structural Supply Crunch, Morgan Stanley Says

Memory Price Surge Sparks Structural Supply Crunch, Morgan Stanley Says

Memory chip prices have spiked more than sixfold in the past year, a shift Morgan Stanley analysts describe as structural. Forecasts cited in the analysts' note project the memory market to expand from roughly $220 billion in 2025 to about $890 billion in 2026, driven primarily by price increases tied to surging demand for AI-focused memory such as…

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…

No Clear Dominant in Quantum Computing, Analysts Say; Pure-Play Firms Hold Modest Slices of a Large Future Market

No Clear Dominant in Quantum Computing, Analysts Say; Pure-Play Firms Hold Modest Slices of a Large Future Market

Analysts at Bernstein conclude that multiple hardware approaches - including superconducting, trapped-ion and neutral-atom systems - all retain competitive advantages, making a single dominant vendor unlikely. Bernstein expects meaningful commercial quantum advantage around 2030, sizes the long-term addressable market at $90 billion to $170 billion…

The Guidance Problem: Why Broadcom Is Vulnerable Despite AI Hype

The Guidance Problem: Why Broadcom Is Vulnerable Despite AI Hype

Broadcom's guidance note that gross profit margins will continue to fall is a clear structural headwind for a stock trading at premium multiples. Fundamentals still look strong, but the market is paying a very high price for near-term margin stability. This trade idea proposes a short-swing (45 trading days) position sized to the risk, with explici…

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…

Why a U.S.-Iran Deal Could Tighten, Not Ease, Fed Policy

Why a U.S.-Iran Deal Could Tighten, Not Ease, Fed Policy

Bank of America analysts caution that a prospective U.S.-Iran agreement, while removing a geopolitical premium, could leave crude oil in a price band that increases inflationary pressure just enough to deter Federal Reserve rate cuts and potentially lead to further tightening instead of relief markets recently priced in.

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …